Inventor · disambiguated record
Wayne Fairbrother
Also filed as: FAIRBROTHER WAYNE · FAIRBROTHER WAYNE J · FAIRBROTHER WAYNE JOHN
22 granted patents·23 pending applications·560 citations·filing 1998–2025
96Inventor score
Top patents by PatentIndex Score
45 records- 0198US7244851B2Inhibitors of IAPGENENTECH INC·Filed 2005·Granted Jul 17, 2007·141 cites·21 claims
- 0296US9539251B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2013·Granted Jan 10, 2017·24 cites·14 claims
- 0395US11110087B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2021·Granted Sep 7, 2021·5 cites·29 claims
- 0495US8114893B2Compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Granted Feb 14, 2012·43 cites·20 claims
- 0595US7345081B2Azabicyclo-octane inhibitors of IAPGENENTECH INC·Filed 2005·Granted Mar 18, 2008·62 cites·20 claims
- 0694US11590128B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2022·Granted Feb 28, 2023·3 cites·7 claims
- 0794US11413282B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2016·Granted Aug 16, 2022·4 cites·10 claims
- 0893US10993942B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2020·Granted May 4, 2021·3 cites·30 claims
- 0993US8518970B2Compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2012·Granted Aug 27, 2013·29 cites·25 claims
- 1092US8232273B2Heterocyclic compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Granted Jul 31, 2012·28 cites·31 claims
- 1192US8168645B2Arylsulfonamide compoundsBAELL JONATHAN BAYLDON·Filed 2007·Granted May 1, 2012·30 cites·15 claims
- 1290US7399869B2Fibroblast activation protein inhibitor compounds and methodsGENENTECH INC·Filed 2006·Granted Jul 15, 2008·23 cites·21 claims
- 1390US2024180901A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1488US2023255959A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1587US2024000776A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1687US2024108616A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 1786US7063961B2Heregulin variantsGENENTECH INC·Filed 2002·Granted Jun 20, 2006·24 cites·10 claims
- 1885US8110568B2Inhibitors of IAPCOHEN FREDERICK·Filed 2010·Granted Feb 7, 2012·7 cites·4 claims
- 1984US2023226045A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2023·Application pending·0 cites
- 2082US9067928B2Compounds and methods of useGENENTECH INC·Filed 2013·Granted Jun 30, 2015·5 cites·24 claims
- 2182US7067274B2Compositions and methods for the screening pro-apoptotic compoundsBURNHAM INST·Filed 2004·Granted Jun 27, 2006·27 cites·4 claims
- 2282US6136558AHeregulin variantsGENENTECH INC·Filed 1998·Granted Oct 24, 2000·46 cites·32 claims
- 2381US6387638B1Heregulin variantsGENENTECH INC·Filed 1998·Granted May 14, 2002·51 cites·24 claims
- 2481US2022265642A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2022·Application pending·0 cites
- 2579US11666581B2PROTAC antibody conjugates and methods of useGENENTECH INC·Filed 2018·Granted Jun 6, 2023·2 cites·22 claims
- 2679US2022008413A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2021·Application pending·0 cites
- 2778US2022211696A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2021·Application pending·0 cites
- 2876US8980837B2Inhibitors of IAPCOHEN FREDERICK·Filed 2012·Granted Mar 17, 2015·2 cites·16 claims
- 2976US2025152582A1Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitorGENENTECH INC·Filed 2025·Application pending·0 cites
- 3071US2025129125A1Macrocyclic compounds and methods of use thereofGENENTECH INC·Filed 2024·Application pending·0 cites
- 3170US7563583B2Heregulin variantsGENENTECH INC·Filed 2006·Granted Jul 21, 2009·1 cites·15 claims
- 3269US2023330102A1Protac antibody conjugates and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 3366US2009148921A1Compositions and methods for enhancing apoptosisGENENTECH INC·Filed 2006·Application pending·0 cites
- 3461US2007299052A1Inhibitors of IAPGENENTECH INC·Filed 2007·Application pending·0 cites
- 3560US12187816B2Macrocyclic compounds and methods of use thereofGENENTECH INC·Filed 2021·Granted Jan 7, 2025·0 cites·16 claims
- 3660US2004171554A1Compositions and methods for enhancing apoptosisGENENTECH INC·Filed 2003·Application pending·0 cites
- 3759US2013143824A1Compositions and methods for enhancing apoptosisGENENTECH INC·Filed 2012·Application pending·0 cites
- 3858US2023391766A11-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancerGENENTECH INC·Filed 2023·Application pending·0 cites
- 3958US2023271944A11-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxa|mide derivatives as vhl inhibitors for the treatment of anemiaGENENTECH INC·Filed 2023·Application pending·0 cites
- 4056US2008146808A1Azabicyclo-octane inhibitors of iapGENENTECH INC·Filed 2008·Application pending·0 cites
- 4155US2012058953A1Compositions and methods for enhancing apoptosisDESHAYES KURT·Filed 2011·Application pending·0 cites
- 4255US2008280856A1Fibroblast Activation Protein Inhibitor Compounds and MethodsGENENTECH INC·Filed 2008·Application pending·0 cites
- 4354US2011098305A1Arylsulfonamide compounds, compositions and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Application pending·0 cites
- 4453US2011039324A1Compositions and methods for enhancing apoptosisGENENTECH INC·Filed 2010·Application pending·0 cites
- 4552US2006246471A1Compositions and methods for screening pro-apoptotic compoundsBURNHAM INST·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wayne Fairbrother files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →